Effects of losartan on the treatment of posttransplant erythrocytosis.
Erythrocytosis is a relatively common complication of renal transplantation. Recent observations indicate that angiotensin-converting enzyme inhibitors correct renal transplant erythrocytosis. Other drugs to inhibit the renin-angiotensin system have been developed recently. The newest of these is losartan, a specific antagonist of the angiotensin II type I receptor. We report three patients in which the use of losartan controlled posttransplant erythrocytosis. Our findings suggest that losartan can be effective and safe in the treatment of posttransplant erythrocytosis.
Navarro
J F
JF
Department of Nephrology, Hospital Ntra. Sra. de Candelaria, S/C de Tenerife, Spain.
García
J
J
Macía
M
M
Mora
C
C
Chahin
J
J
Gallego
E
E
Méndez
M L
ML
del Castillo
N
N
D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D011086:Polycythemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
D000804:Angiotensin II; D019808:Losartan